Protalix BioTherapeutics (PLX) Convertible Debt (2013 - 2023)

Protalix BioTherapeutics' Convertible Debt history runs 11 years deep, the most recent figure standing at $20.4 million for Q4 2023.

• In Q4 2023, Convertible Debt fell 27.56% year-over-year to $20.4 million; the TTM figure through Dec 2023 stood at $20.4 million (down 27.56% YoY), while the FY2023 annual figure was $20.4 million, down 27.56% from the prior year.
• Convertible Debt was $20.4 million for Q4 2023 at Protalix BioTherapeutics, up from $20.1 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $53.5 million in Q3 2020 to a low of $20.1 million in Q2 2023.
• Historically, Convertible Debt has averaged $37.1 million across 5 years, with a median of $28.2 million in 2022.
• The sharpest annual moves came in 2020 and 2021: Convertible Debt rose 6.66% in 2020, then tumbled 48.01% in 2021.
• A 5-year view of Convertible Debt shows it stood at $51.0 million in 2019, then advanced by 5.0% to $53.5 million in 2020, then plunged by 47.88% to $27.9 million in 2021, then increased by 1.08% to $28.2 million in 2022, then dropped by 27.56% to $20.4 million in 2023.
• The last three Convertible Debt figures came in at $20.4 million (Q4 2023), $20.1 million (Q2 2023), and $28.3 million (Q1 2023), per Business Quant data.